跳至主要内容
临床试验/NCT02948894
NCT02948894Unknown2 期

Mandibular Advancement Device for Treatment of Obstructive Sleep Apnea and Its Impact on Cardiac Remodeling

National University of Singapore4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年5月1日最近更新:
适应症

试验速览

阶段
2 期
入组人数
100
试验地点
4
主要终点
Apnea-Hypopnea Index

研究概览

简要总结

Primary aim: The MOSAIC trial aims to assess the impact of a mandibular advancement device (MAD) on Apnea-Hypopnea Index (AHI) in Asian patients with Heart Failure with reduced Ejection Fraction (HFrEF) and obstructive sleep apnea (OSA). The investigators hypothesize that the AHI was 60% lower after 3-month treatment with MAD than with sham MAD.

Secondary aims: The investigators also aim to determine i. the interaction between ethnicity (Chinese, Malay, Indians) and the effects of MAD in lowering AHI; ii. the effect of MAD on cardiac remodeling (LVEDVI assessed by cardiac magnetic resonance imaging [CMR]); iii. the characteristic craniofacial skeletal anatomy (using coned beam computed tomography [CT]) associated with OSA in Asian patients with HFrEF; iv. the association between self-reported adherence to MAD and cardiac remodeling; v. the effects of MAD on biomarkers of HF (N-terminal pro-B-type natriuretic peptide [NT-proBNP],high sensitivity cardiac troponin T [hs cTnT], high-sensitivity C-reactive protein [hs-CRP], and ST2);

Rationale: OSA is associated with incident HF. The investigators will study Asian patients because a body of evidence suggests mechanisms for OSA differ between Asians and Caucasians. While obesity is the major contributing factor in Caucasians, craniofacial skeletal anatomy (short mandible, maxilla, and cranial base and a large mandibular volume) plays an important role in the development of OSA among Asians. Using cone beam CT, it has been shown that Asians have shorter mandibular, maxillary, and cranial base lengths and a greater mandibular volume compared with Caucasians. Using a MAD to adjust maxillary-mandibular juxta-positioning to maintain a patent airway may be an ethnic-specific approach to treat OSA in Asians.

详细描述

The MOSAIC is a randomized, double-blind, placebo-controlled, cross-over trial to be conducted at the National University Health System. It is a collaboration between the National University Heart Centre Singapore, the Faculty of Dentistry, and the University Medicine Cluster. Apart from evaluating the effect of MAD on AHI- a conventional measure of OSA severity, the investigators will also explore the effect of MAD on cardiac remodeling. Adverse remodeling equates to progressive worsening of cardiac function, and slowing or reversing such remodeling is a goal of HF therapy. Ventricular measures including LV end diastolic volume index (LVEDVI) have proven to be meaningful surrogates reflecting the beneficial effect of therapeutic agents such as angiotensin-converting enzyme inhibitors and beta-adrenergic blocking agents on the remodeling process and on "hard" morbid and mortal end points.

Screening. Patients (n=200) will undergo polysomnography and coned beam CT if the following criteria are met: (i) Asians (Chinese, Malay or Indians) living in Singapore (ii) symptomatic HF (NYHA classes II-III) due to ischemic cardiomyopathy, (iii) LVEF <45% (as determined by echocardiography) (iv) clinical stability for ≥1 month, (v) optimal medical therapy including a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, and a beta-blocker. The doses of these background medications should be stable for ≥1 month. Exclusion criteria:-(i) known OSA on treatment, (ii) acute coronary syndrome within the preceding 3 months, (iii) severe valvular heart disease, (iv) sustained ventricular arrhythmia, (v) stroke with residual neurological deficits, (vi) contraindication to CMR such as a pacemaker or cardioverter-defibrillator implant.

Overnight Polysomnography will be performed at the National University Health System (NUHS) Cardiosleep Research Laboratory following a standard laboratory protocol with a computerized recording system. All sleep studies will be scored according to the American Academy of Sleep Medicine guidelines, by an experienced sleep physician. Apnea is defined as a complete cessation in airflow lasting ≥10 s and hypopnea as a reduction in airflow or thoraco-abdominal movement by ≥50% for ≥10 s. Apneas will be classified as (i) obstructive if thoraco-abdominal movement was present during the apnea; (ii) central if thoraco-abdominal movement was absent; and (iii) mixed if thoraco-abdominal movements were both present and absent during the period of airflow cessation.

Coned beam CT. To determine the specific craniofacial anatomy that predicts OSA in Asians with HFrEF, the patients (regardless of the polysomnography results) will undergo a coned beam CT for craniofacial profiling at the Faculty of Dentistry. Image acquisition will be performed during quiet tidal breathing with subjects supine and with a neutral head position. Landmarks will be identified and measurements performed as previously reported. Tongue area will be measured by tracing the contours on the sagittal plane, whereas lateral wall thickness and parapharyngeal fat will be quantified on the axial plane. To determine tongue volume, the tongue limits will be identified and traced manually on each axial image obtained. Volumetric reconstructions will be performed to determine mandible, tongue, and airway volume.

Randomization. After the initial evaluation, the patients found to have OSA (estimated prevalence 50%, n=100) with an AHI of ≥ 15 events/hr will be randomized to (i) MAD followed by sham MAD (non-advanced device) or (ii) sham MAD followed by MAD, with a 2-week washout period in between. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months, with comprehensive testing (polysomnography, echo, and biomarker assays) at the end of each 3-month period. The patients would also keep a daily record of time overnight wearing the device (adherence).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Asians (Chinese, Malay or Indians) living in Singapore
  • Symptomatic HF (NYHA classes II-III) due to ischemic cardiomyopathy
  • LVEF <45% (as determined by echocardiography)
  • Clinical stability for ≥1 month
  • Optimal medical therapy including a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, and a beta-blocker. The doses of these background medications should be stable for ≥1 month.

排除标准

  • Known OSA on treatment
  • Acute coronary syndrome within the preceding 3 months
  • Severe valvular heart disease
  • Sustained ventricular arrhythmia
  • Stroke with residual neurological deficits
  • Contraindication to CMRsuch as a pacemaker or cardioverter-defibrillator implant.

结局指标

主要结局

Apnea-Hypopnea Index

时间窗: 3 months

次要结局

  • cardiac remodeling (Left ventricular end diastolic volume index)(3 months)
  • biomarkers of heart failure(3-months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chi-Hang Lee

Associate Professor

National University of Singapore

研究点 (4)

Loading locations...

相似试验